Rolls Out New and Improved Ultrasonic Device for Topical Lidocaine Delivery
FRANKLIN, Mass., Feb. 7/PRNewswire-FirstCall/-- Sontra Medical Corporation
(Nasdaq: SONT) announced today that it has introduced its Generation 1.75
SonoPrep(R) skin permeation device for topical lidocaine delivery. The
upgraded device has a new and improved ultrasonic hand piece and fluid
delivery system that is much smaller, simpler and less expensive to
manufacture. The new hand piece also will be incorporated into the 2nd
generation SonoPrep skin permeation device scheduled to be introduced in May
2006. The 2nd Generation SonoPrep device is more portable with improved
ergonomics, a replaceable battery, and a digital display that monitors
operation. "The initial response from intravenous and pediatric nurses has
been very positive," stated Barry Marston, Sontra's Vice President of Sales
and Marketing. "The practitioners appreciate the smaller, more ergonomic hand
piece that is easier to apply and more comfortable for the patients."
The SonoPrep ultrasonic skin permeation employs low frequency ultrasound
to penetrate the skin's outermost layer, the stratum corneum. This simple and
fast (average 15 second) treatment creates an imperceptible window through the
skin that enables molecules to pass through with 100 times greater efficiency
than intact skin. The SonoPrep ultrasonic skin permeation device makes the
skin permeable for up to twenty-four hours for continuous non-invasive
diagnostics such as glucose monitoring and transdermal drug delivery.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science.
Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with
technical competencies in transdermal drug formulation, delivery systems and
biosensors is creating a new paradigm in transdermal drug delivery and
diagnosis. The SonoPrep technology is being developed for several billion
dollar market opportunities, including continuous glucose monitoring and the
transdermal delivery of large molecule drugs and vaccines. Sontra is currently
marketing the SonoPrep device and procedure tray for use with topical
lidocaine to achieve rapid (within five minutes) skin anesthesia.
Contact:
Sean Moran, Sontra Medical CFO
508-530-0334
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected technological
advances and availability of the second-generation SonoPrep device, the
expected benefits and efficacy of the SonoPrep device in connection with
diagnostics, vaccine delivery, glucose monitoring and transdermal drug
delivery, Sontra's expected ability to develop, market and sell products based
on its technology; the expected market opportunities, distribution and market
acceptance of the SonoPrep device and technology, and Sontra's business,
research, product development, regulatory approval, marketing and distribution
plans and strategies. Statements that are not historical facts, including
statements about our beliefs and expectations, are forward-looking statements.
Such statements are based on our current expectations and are subject to a
number of factors and uncertainties, which could cause actual results to
differ materially from those described in the forward-looking statements. The
following important factors and uncertainties, among others, could cause
actual results to differ materially from those described in these forward-
looking statements: our technology is new and we may experience adverse
results in research and development efforts, product development, clinical
trials, product evaluations, commercialization efforts, product distribution
and market acceptance; markets for our products may develop slower than
expected, or not at all; our sales cycle is lengthy and we are still
developing sales and marketing strategies which may or may not prove
effective; the SonoPrep device may not prove effective in connection with
diagnostics, vaccine delivery, glucose monitoring and/or transdermal drug
delivery; we may experience difficulties or delays in obtaining regulatory
approvals to market products resulting from development efforts or
difficulties or delays associated with sources of regulatory-approved
transdermal drugs and vaccines; failure to obtain and maintain patent
protection for discoveries or commercial limitations imposed by patents owned
or controlled by third parties would have an adverse effect on us; we depend
upon strategic partners and third-party distributors to develop,
commercialize, market and sell products based on our work; and we require
substantial additional funding to conduct research and development and to
expand commercialization, distribution and marketing activities. For detailed
information about factors that could cause actual results to differ materially
from those described in the forward-looking statements, please refer to
Sontra's filings with the Securities and Exchange Commission, including
Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking
statements represent management's current expectations and are inherently
uncertain. We do not undertake any obligation to update forward-looking
statements made by us.
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran, CFO of Sontra Medical,
+1-508-530-0334
|
